D/E 0.00 — least levered decile in Healthcare (≈10th pctile)
P/E18.2xA-
P/E 18.2 — cheaper than most Healthcare peers (≈25th pctile)
PEG0.92proxyB+
PEG 0.92 — near fair value, classic Lynch benchmark (1.0) · PEG proxy: P/E ÷ revenue growth % (true PEG requires forward EPS estimates, not in Finnhub free tier).
Forward price target — the 1-year figure is the analyst consensus where the stock is covered; the 5- and 10-year figures compound our earnings estimate from there. The DCF below is a separate cross-check on intrinsic value (what it's worth today), not another target.
Quality-growth score · 84.6
Quality0.91
Growth1.00
Value0.67
Why this score
Durable high returns
Entry · Margin of safety
52-week rangeNear 52-week high
3% off the 12-month high
vs DCF fair value7% aboveest. fair value ~$29
Quality signals · context only
Gross profitability45% · A-gross profit ÷ total assets (Novy-Marx)
ROIC20.9% · Areturn on invested capital — not score-weighted
Why now
Firdapse’s monopoly in the ultra‑rare LEMS market fuels a profit margin of 37.1% and drives free cash flow of $208m, while revenue is still expanding at 19.8% YoY – a rare combo of cash generation and growth that the market is already pricing in at a modest PE 18.2. The thesis rests on the fact that this cash‑rich, high‑margin franchise can keep compounding earnings without dilution, making the current price a launchpad for sustained upside.
Moat
Firdapse is the sole FDA‑approved therapy for LEMS, protected by exclusive patents and a narrow patient pool that creates high switching costs and pricing power, which translates into a ROE of 21.9%—clearly derived from its category‑lead pricing advantage. The company’s zero‑debt balance sheet further amplifies returns on that moat, limiting competitors’ ability to out‑spend Catalyst on launch and market capture.
Risk
The stock’s upside is razor‑thin—analyst consensus lifts the price to only $31.67 versus today’s $31.47 and the 52‑week high sits at $32.56, leaving little room for error if Firdapse sales stall or if a new seizure drug erodes Fycompa’s market share. A slowdown in the 19.8% revenue growth trajectory would compress margins and trigger a sell‑off, confirming the bear case when the price slips below the 52‑week low of $19.05.
Horizon
1-3 yr $31.67 (3-analyst consensus) — multiple re-rating thesis requires a catalyst. 5 yr $39.98 at ~5% CAGR — dividend + buyback compounding. 10 yr $51.27 if the moat survives secular pressure.
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.
Position sizing · CPRX
$
%
%
Shares to buy
63
Position size
$1,983
4.0% of portfolio
Stop price
$23.60
25% below $31.47
$ at risk if stopped
$495.65
budget $500.00 · 1% of portfolio
Math only — share count is floor(portfolio × risk% ÷ (price × stop%)). Doesn't account for commissions, slippage, gap risk, or position-correlation across your book. Inputs persist locally; never sent to the server. Not investment advice.
Catalyst Pharmaceuticals, Inc. (CPRX): score, valuation & FAQ
Catalyst Pharmaceuticals, Inc. (CPRX) is a Biotechnology company that scores 84.6 out of 100 on the Bull Rankings quality-growth model — a strong reading. The score blends three pillars — quality (durable returns, healthy margins, low leverage), growth (revenue and earnings), and value (valuation versus sector peers) — into one number, refreshed daily; it is a screen, not a buy recommendation.
Its strongest graded signals are D/E (A), P/E (A-) and Rev (B+). On valuation, CPRX sits about 7% above our discounted-cash-flow fair value (i.e. the DCF flags it as rich).
Is CPRX a good stock to buy?
Bull Rankings scores CPRX 84.6 out of 100 on its quality-growth model, which is a strong reading. That is driven by D/E (A), P/E (A-) and Rev (B+). A score is a quantitative screen of Catalyst Pharmaceuticals, Inc.'s fundamentals, not personalised financial advice — weigh it against your own time horizon and risk tolerance, and read the risk factors below before acting.
Why does CPRX score 84.6 on Bull Rankings?
The quality-growth score blends three pillars — quality (returns on capital, margins, leverage, earnings quality), growth (revenue and earnings expansion), and value (valuation versus sector peers). CPRX earns its highest marks on D/E (A), P/E (A-) and Rev (B+). Each pillar is graded against sector-aware thresholds, then combined into the single 0–100 score.
Is CPRX overvalued or undervalued?
Based on $31.47, CPRX sits about 7% above our discounted-cash-flow fair value (i.e. the DCF flags it as rich). It trades at a 18.2x× P/E (graded A-). Discounted-cash-flow estimates are sensitive to growth and discount-rate assumptions, so treat this as a cross-check, not a price target.
What are the main risks of investing in CPRX?
The stock’s upside is razor‑thin—analyst consensus lifts the price to only $31.67 versus today’s $31.47 and the 52‑week high sits at $32.56, leaving little room for error if Firdapse sales stall or if a new seizure drug erodes Fycompa’s market share. A slowdown in the 19.8% revenue growth trajectory would compress margins and trigger a sell‑off, confirming the bear case when the price slips below the 52‑week low of $19.05.
Bull Rankings is an automated fundamentals screen for research and education. It is not investment advice, and nothing here is a recommendation to buy or sell any security. Do your own research and consider consulting a licensed financial adviser.